Skip to content
‹ Back to IndustriesHealthcare

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz, Chief Medical Physicist at Texas Oncology, brings both professional expertise and personal experience as a breast cancer survivor to her role in advancing cancer care. Over 23 years at Texas Oncology, she champions technology adoption and AI integration in oncology while emphasizing the importance of human oversight in clinical applications.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Therapanacea on MarketScale.

By Jeanine Mendes · Medical PhysicsCancer CareArtificial IntelligenceOncology
Share

Key takeaways

01

Dr. Rosencranz is a five-year breast cancer survivor whose personal experience informs her approach to patient empathy and personalized care delivery.

02

AI applications in oncology like auto-contouring and treatment planning show significant advancement potential, but require consistent human leadership and oversight.

03

Texas Oncology reaches many demographics, including rural areas where travel to urban centers is hard, while staying current with the highest technology available.

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Dr. Dana Rosencranz serves as the Chief Medical Physicist at Texas Oncology, merging her professional expertise with her personal experience as a cancer survivor. Her insights into patient care have been shaped not only by her extensive career in oncology but also by her journey as a breast cancer survivor over the past five years. This unique blend of perspectives enhances her ability to connect with patients while driving advancements in medical physics and oncology care.

A dual perspective: Provider and patient

The day Dr. Rosencranz received her cancer diagnosis is etched in her memory. As a seasoned professional familiar with the terminology, she anticipated the diagnosis upon hearing her radiologist mention "spiculated margins." "I kinda knew before the official diagnosis that I have cancer," she reflected, marking the start of her journey from a provider to a patient. This dual experience allows her to empathize deeply with her patients, understanding firsthand the mix of fear and uncertainty that comes with such news.

Dr. Rosencranz's medical journey enhanced her appreciation for personalized care. Her professional network, including friendships with her future chemotherapy and radiation oncologists, provided her with support that most patients lack. This intersection of professional and personal support enables her to empathize with patients on a level beyond clinical assessments.

Embracing innovation in oncology

Throughout her 23-year tenure at Texas Oncology, Dr. Rosencranz has witnessed the evolution of technology in cancer care. She praises the organization's dedication to providing top-tier cancer treatment, particularly in rural areas where travel to urban centers can be challenging. "Texas Oncology penetrates through so many demographics... we are staying online with the highest technology out there," she stated.

Dr. Rosencranz is enthusiastic about the role of artificial intelligence in oncology. She identifies applications like auto-contouring and treatment planning as areas where AI is making significant advancements. However, she emphasizes the necessity of human oversight: "You still need that human leadership in anything that you do." Her message to vendors in the tech industry is straightforward: consistent testing and transparency are essential to building trust and understanding as AI becomes more prevalent in clinical settings.

Her advocacy for AI in oncology is founded on the potential she sees for the technology to transform care, facilitating both efficiency and the creation of personalized treatment plans. Dr. Rosencranz envisions a future where human expertise and AI work in tandem to enhance patient outcomes and push the limits of what's possible in cancer treatment.

Therapanacea

Part of this channel

Therapanacea

AI-powered precision oncology

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

JM
Jeanine MendesMarketing, TheraPanacea
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

TheraPanacea's CEO says software, not hardware, will scale radiotherapy

TheraPanacea's CEO says software, not hardware, will scale radiotherapy

TheraPanacea CEO Nikos Paragios said at ASTRO 2026 in Boston that vendor-agnostic AI software like ART-Plan can raise radiotherapy throughput on existing machines. A February 2025 Lancet Oncology study puts the global linac shortfall at 30%, with 36 of 181 countries owning no linac, limiting how far software alone can go.

  • 01A February 2025 Lancet Oncology study found a global median Linac Shortage Index of 130, a 30% capacity shortfall, and 36 of 181 countries with no linac at all.
  • 02Bundled adaptive systems already exist: Varian’s Ethos won FDA clearance in February 2020 and RaySearch demoed automated replanning at ASTRO, but buyers still need to validate acceptability and sign-off workflows.

Oct 29, 2026

Berg Insight expects 160 million home medical monitors in care programs by 2030

Berg Insight expects 160 million home medical monitors in care programs by 2030

Prescribed connected home medical monitors are forecast to grow from 92.7 million in 2025 to 159.7 million by 2030. Fastest growth is in diabetes, remote ECG and medication compliance, spread across many suppliers. Berg and IoT Business News argue value depends on integrating data into workflows.

  • 01159.7 million prescribed home medical monitors expected by 2030, growing at 11.5 percent annually from 92.7 million in 2025.
  • 02Sleep therapy is the largest connected segment, followed by diabetes with 19.5 million connections at end of 2025, with fastest future growth in diabetes, remote ECG and medication compliance monitoring.
  • 03Clinical value increasingly depends on integrating data across devices into workflows: vendors combine hardware, software, analytics and interoperability with existing healthcare systems.

Oct 26, 2026

Zocdoc's first acquisition in nearly 20 years is an insurance checker

Zocdoc's first acquisition in nearly 20 years is an insurance checker

Zocdoc has bought Sohar Health, its first acquisition in nearly 20 years. Sohar's software finds and verifies a patient's insurance coverage from a name and birth date. Zocdoc wants that check to work across its Care Access Network, which lets insurers, consumer apps and AI tools embed Zocdoc's clinician search and scheduling on their own websites and apps.

  • 01After nearly 20 years without an acquisition, Zocdoc's first purchase is the insurance check that sits between a patient's search and a booked appointment.
  • 02For practices that pay Zocdoc per booking, the sharper question is how often coverage verified at booking matches what the front desk confirms at check-in.

Oct 24, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

JM
Jeanine Mendes

Marketing

TheraPanacea

DD
Dr. Dana Rosencranz

Chief Medical Physicist

Texas Oncology

Chief Medical Physicist combining breast cancer survivor insights with expertise in AI integration and personalized cancer treatment.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512